Janssen's Amivantamab and Docetaxel Combo in NSCLC Enters Phase 1/2 Trials
Janssen is conducting Phase 1/2 study to evaluate the combination of amivantamab and docetaxel in metastatic NSCLC patients without oncogenic driver mutations.
Phase I
Oncology / NSCLC
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase 1/2 trial of Janssen's amivantamab and docetaxel combination therapy is significant as it targets a niche patient population in metastatic NSCLC. Positive trial outcomes could enhance Janssen's competitive positioning and influence treatment paradigms in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include the determination of the recommended Phase 2 dose and subsequent efficacy results from the expansion phase.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.